Abstract
Background: Mantle cell lymphoma (MCL) is a rare, aggressive and incurable subtype of B-cell non-Hodgkin lymphoma (NHL) with a median overall survival of 5–7 years. Lenalidomide is an immunomodulatory agent, with clinical activity in relapsed or refractory (R/R) MCL patients. Among other effects, lenalidomide is known to enhance the formation of immunological synapses between MCL and lytic T/natural killer (NK) cells. The small GTPase Ras homolog family member A (RHOA) acts as a molecular switch controlling a wide variety of cellular processes such as cytoskeleton organization, cell proliferation, differentiation and migration.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
